Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who are willing and able to sign a written consent form
- People who have laboratory-confirmed documentation of their tumour type and any relevant genetic mutations before starting the study drug (where this applies to their specific group in the trial)
- People whose cancer either has no standard treatment available, or whose standard treatment has not worked, cannot be tolerated, or cannot be accessed — or who have chosen not to have standard treatment (this does not apply to people in the newly diagnosed pancreatic ductal carcinoma group)
- People who are able to swallow oral (by mouth) medication
- People who have a general health and activity level rated as 0 or 1 on a standard scale used in cancer trials, meaning they are either fully active or have minor limitations on strenuous activity (confirm with trial site)
- People whose heart, blood, liver, and kidneys are functioning adequately
- People who are willing to attend all required visits and complete all study procedures
Who may not be able to join:
- People who have previously been treated with a type of drug called a RAS inhibitor
- People who are currently taking part in another clinical trial or who have received an experimental treatment within the past 4 weeks
- People who have received palliative radiation therapy within the 14 days before the trial begins
- People whose cancer originated in the brain or spinal cord (central nervous system)
- People who have had certain types of stomach or bowel surgery, or who have a digestive condition, that could affect how the body absorbs medication (such as gastric bypass, gastrectomy, Crohn's disease, ulcerative colitis, or short gut syndrome)
- People who have an underlying medical condition, mental health condition, or personal circumstance that, in the trial doctor's judgement, could interfere with safely running the study or assessing its results
- People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the period of the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gerri Lee, Erasca, Inc.
Phone: +1-858-465-6511
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose Limiting Toxicities (DLT); Maximum tolerated dose (MTD); Recommended dose for expansion (RDE); Adverse Events; Plasma concentration (Cmax); Time to achieve Cmax (Tmax); Area under the curve; Half-life
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.